MedTrace Logo

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

NCT06065462 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-12-24

No results posted yet for this study

Summary

To learn if the combination of dostarlimab and LB-100 can help to control ovarian clear cell carcinoma

Conditions

Interventions

DRUG

Dostarlimab

Given by vein (IV)

DRUG

LB-100

GIven by vein (IV)

Sponsors & Collaborators

  • GSK Pharma

    collaborator UNKNOWN

  • Lixte

    collaborator UNKNOWN

  • M.D. Anderson Cancer Center

    lead OTHER

Principal Investigators

  • Amir Jazaeri, M D · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-10
Primary Completion
2027-10-01
Completion
2027-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06065462 on ClinicalTrials.gov